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Collagen is the most abundant protein in animals. A variety of indications are associated with the overproduction of collagen, including fibrotic diseases and cancer metastasis. The stability of collagen relies on the posttranslational modification of proline residues to form (2S,4R)-4-hydroxyproline. This modification is catalyzed by collagen prolyl 4-hydroxylases (CP4Hs), which are Fe(II)-and a-ketoglutarate (AKG)-dependent dioxygenases located in the lumen of the endoplasmic reticulum. Human CP4Hs are validated targets for treatment of both fibrotic diseases and metastatic breast cancer. Herein, we report on 2,2 0 -bipyridinedicarboxylates as inhibitors of a human CP4H. Although most 2,2 0 -bipyridinedicarboxylates are capable of inhibition via iron sequestration, the 4,5 0 -and 5,5 0 -dicarboxylates were found to be potent competitive inhibitors of CP4H, and the 5,5
0 -dicarboxylate was selective in its inhibitory activity. Our findings clarify a strategy for developing CP4H inhibitors of clinical utility.
Ó 2015 Elsevier Ltd. All rights reserved.
Introduction
Collagen is the principle component of bone, connective tissues, and the extracellular matrix in animals. 1 A variety of diseases are associated with the overproduction of collagen, including fibrotic diseases (such as pulmonary fibrosis, renal fibrosis, and hepatic cirrhosis) 2, 3 and cancers. [4] [5] [6] [7] [8] The stability of collagen relies on posttranslational modifications that occur throughout the secretory pathway. 9 The most prevalent of these modifications is the hydroxylation of collagen strands by collagen prolyl 4-hydroxylases (
), which are Fe(II)-and a-ketoglutarate (AKG)-dependent dioxygenases (FAKGDs) located in the lumen of the endoplasmic reticulum. 11 Catalysis by CP4Hs converts (2S)-proline (Pro) residues in protocollagen strands into (2S,4R)-4-hydroxyproline (Hyp) residues ( Fig. 1) , which are essential for the conformational stability of mature collagen triple helices. 12 Importantly, CP4Hs are validated targets for treating both fibrotic diseases 13 and metastatic breast cancer, 7 which in aggregate represent a massive unmet clinical need. Like all enzymes of the FAKGD superfamily, catalysis by CP4Hs requires Fe(II), which is bound by a conserved His-XAsp/Glu. . .X n . . .His motif, as well as the cosubstrates AKG and dioxygen.
14 AKG chelates to enzyme-bound Fe(II) using its C-1 carboxylate and C-2 keto groups, while the C-5 carboxylate group engages in Coulombic interactions with a basic residue (typically arginine or lysine) and additional hydrogen bonds. All FAKGDs are believed to effect catalysis through a similar two-stage mechanism in which AKG is first oxidatively decarboxylated to generate a highly reactive Fe(IV) = O species (ferryl ion), after which the ferryl ion interacts with a hydrocarbon substrate and effects hydroxylation via a radical rebound process. 14 In vertebrates, CP4Hs are known to exist as a 2 b 2 tetramers. In these tetramers, the a-subunit contains the catalytic and substrate-binding domains, and the b-subunit is protein disulfide isomerase, which is a multifunctional protein that is responsible for maintaining the a-subunit in a soluble and active conformation. 11 Three isoforms of the a-subunit, a(I), a(II), and a(III), have been identified in humans. 11 All a-subunit isoforms form tetramers with the b-subunit, which we refer to herein as the CP4H1, CP4H2, and CP4H3 holoenzymes. As the most prevalent of the isoforms, the a(I)-subunit has been characterized extensively. Whereas the structure of the tetrameric complex is unknown, those of individual domains of the a(I)-subunit have provided insight into the manner in which CP4Hs interact with the protocollagen substrate, as well as the means by which the a-subunits dimerize to facilitate formation of the tetramer. [15] [16] [17] The development of CP4H inhibitors has been of keen interest since the mid 1970s. Like many FAKGDs, human CP4Hs are inhibited by simple metal chelators, such as 2,2 0 -bipyridine (1), as well as AKG mimics (Fig. 2) , such as N-oxalyl glycine (2), pyridine-2,4-dicarboxylic acid (3a) and pyridine-2,5-dicarboxylic acid (3b). In general, simple metal chelators are thought to inhibit CP4Hs by iron sequestration, as evidenced by IC 50 -values that are similar to the iron concentration used in assays in vitro. In contrast, AKG mimics are thought to bind competitively in the AKG binding site, using a chelating moiety to interact with the enzymic iron and an additional carboxyl group to form favorable Coulombic interactions with Lys493. 18 Compounds of this nature typically display values of IC 50 or K i that are less than the value of K m for AKG (which is 20 lM for human CP4H1). 19 There are also examples of electrophilic AKG mimics such as coumalic acid 20 and 4-oxo-5,6-epoxyhexanoic acid 21 that appear to inhibit CP4H via covalent modification of the active site. Compounds of this nature could have intriguing chemical and biological utility.
Of the simple AKG mimics, the most potent inhibitor of human CP4Hs reported to date is 3b, which was found to have a K i = 0.8 lM and display modest selectivity for human CP4Hs compared to other FAKGDs, such as the prolyl hydroxylase domaincontaining proteins (PHDs), factor-inhibiting HIF (FIH), and Jumonji domain-containing 2E (JMJD2E). 22, 18 Thus, much work has focused on modification of the 3b scaffold with the intent of generating a cell-active inhibitor that is both potent and selective.
Some examples include the 5-position N-acylsulfonamide derivatives 23 and 2-heterocyclic glycinamide derivatives 24 of 3b ( Fig. 2 ), though these compounds were not developed further due to insufficient activity in cultured cells or intolerable cytotoxicity.
The most potent inhibitor of human CP4Hs identified to date is 2,2 0 -bipyridine-5,5 0 -dicarboxylic acid (4e, Fig. 3 ). 25 Whereas the parent compound 2,2 0 -bipyridine-5-carboxylic acid (5) was found to be a modest inhibitor (IC 50 = 13 lM), 4e was reported to be substantially more potent (K i = 185 nM). 25 The inhibitory mechanism of this compound is, however, not known. 1 itself is well known to inhibit human CP4Hs via iron sequestration rather than enzymic binding. Although structure-activity relationships (SARs) suggest that enzymic binding contributes to inhibition by 4e, 25 the role of iron sequestration is unclear. Herein, we investigate 2,2 0 -bipyridinedicarboxylates as inhibitors of human FAKGDs, both in terms of the relevant inhibitory mechanism(s) and optimum geometry for inhibition. We access a library of seven 2,2 0 -bipyridinedicarboxylates and assess the ability of each to sequester iron and bind to a CP4H. We find that both 2,2 -bipyridine-4,5 -dicarboxylate (4c) and 4e are nanomolar inhibitors of a CP4H, though both also bind to free Fe(II). Significantly, we discover that 4c, but not 4e, binds to a human PHD. These data provide a roadmap for developing potent, selective inhibitors of human CP4Hs.
Results and discussion

2,2
0 -Bipyridinedicarboxylate library
We accessed a focused library of 2,2 0 -bipyridinedicarboxylates (4a-g) (Fig. 3) . The symmetric members of the library, 2,2 0 - bipyridine-3,3 0 -dicarboxylic acid (4a), 2,2 0 -bipyridine-4,4 0 -dicarboxylic acid (4b), 4e, and 2,2 -bipyridine-6,6
0 -dicarboxylic acid (4g), were obtained from commercial vendors. The asymmetric members were synthesized by a 4-step route in which the key 2,2 0 -bipyridine intermediates were accessed by the palladium-catalyzed 2-pyridylation of the corresponding pyridine N-oxides (Scheme 1). [26] [27] [28] This route afforded 4c, 2,2 0 -bipyridine-4,6 0 -dicarboxylic acid (4d), and 2,2 0 -bipyridine-5,6 0 -dicarboxylic acid (4f) in overall yields of 53%, 36%, and 15%, respectively.
Iron sequestration
To begin our analysis, we evaluated 4a-g as iron chelators. We performed titration experiments to determine the half-maximal concentration required to form a complex with 20 lM Fe(II) (Fe 20 -EC 50 ) at pH 7.0, taking advantage of the strong absorption of complexes of 1 and related analogues with Fe(II) ( Table 1) . Along with an estimation of stoichiometry obtained with Job's method, the Fe 20 -EC 50 value provides a comparative metric for iron affinity. With the exception of 4a and 4g, all members of the library were capable of forming distinct red complexes with Fe 20 -EC 50 values in the micromolar range (see: Supporting information). Because 1 is already known to inhibit CP4Hs, these results suggest that most of these ligands would inhibit CP4H1 by sequestering iron under iron-limiting conditions.
CP4H binding
To identify compounds that inhibit human CP4H1 through enzymic binding rather than iron sequestration, we next sought to determine the extent to which 1 and 4a-g form a complex with Fe(II) under CP4H assay conditions. Typical in vitro assays for human CP4Hs employ a tris(hydroxymethyl)aminomethane (Tris) buffer. Although Tris is known to form complexes with metal ions, 29 , but that the subsequent addition of either sodium ascorbate or DTT allowed for complex formation.
Given these results and the requirement of ascorbate for hydroxylase activity, the design of assay conditions that preclude the formation of Fe(II) complexes with 1 and related analogues is highly unlikely. Thus, we next sought to develop in vitro screening conditions for human CP4Hs such that the inhibitory effect of iron sequestration would be minimal. We chose an initial screening concentration of 10 lM, which is substantially below the concentration of FeSO 4 (50 lM) used in the assay. Importantly, 1 showed virtually no inhibition under these screening conditions whereas 3b showed significant inhibition (Fig. 4A) , which validates these conditions for the discovery of compounds where the primary inhibitory mechanism is other than merely iron sequestration. Although most of the compounds screened under these conditions showed little to no inhibition, both 4e and 4c were found to be potent inhibitors (more than 90% reduction of CP4H activity) and 4b was found to be a modest inhibitor that is similar in potency to 3b (Fig. 4A) . In subsequent dose-response experiments, the inhibition curves for 4e and 4c were found to be sigmoidal ( Fig. 4B ) with IC 50 values in the low micromolar range (Table 2 ). Yet, the inhibition curve for 4b was found to be non-sigmoidal (see: Supporting information), which suggests a mixed inhibitory mechanism wherein iron sequestration becomes a contributing factor at higher concentrations (supported by the observation of a red color in the assay solutions). These data suggest that CP4H1 is inhibited strongly by 2,2 0 -bipyridinedicarboxylates of two different geometries with almost equal potency, and that the inhibition does not rely upon iron sequestration.
To understand further the potent inhibition observed for 4e and 4c, we next probed the kinetic mechanism of these compounds. Human CP4Hs have been shown previously to display an ordered ter-ter mechanism in which AKG first binds to the CP4HÁFe(II) complex, after which O 2 and the peptide substrate bind in an ordered fashion. 19 Lineweaver-Burke analyses confirmed that 4e
and 4c both function as competitive inhibitors with respect to AKG (Fig. 5) , which suggests that they bind to CP4H1 in a manner that requires enzymic iron. Based upon the observed competitive inhibition, we used the Cheng-Prussoff equation to estimate values of K i for these compounds ( Table 2) . We found that 4e and 4c inhibit human CP4H1 with K i values in the nanomolar range. These K i values should be taken as upper limits, as it is difficult to take into account the fraction of each that is present in complexes with free iron under assay conditions. Although the competitive inhibition observed here should be interpreted with caution in the absence of structural information, these data are consistent with a mechanism in which 4e and 4c inhibit human CP4H1 by binding in the AKG binding pocket. In addition, we tested the biphenyl analogs of 4e and 4c and found that the pyridyl nitrogens were essential for detectable inhibition (data not shown), providing further support for a mechanism in which coordination of the enzymic iron is a requirement. It is interesting to note the SARs observed above for the 2,2 0 -bipyridinedicarboxylates parallel that of the pyridinedicarboxylates. For example, human CP4H1 is inhibited by both 3a and 3b, where the geometry of 3b is preferred compared to that of 3a.
18 Similarly, both 4e and 4c (reminiscent of 3b and 3a, respectively) are accommodated in the active site, where the geometry of 4e appears to be preferred compared to that of 4c. Yet, it is also important to note that 4e and 4c are substantially more potent than the corresponding pyridinedicarboxylates. For example, comparing 3b and 4e and assuming energetically similar interactions with the assay buffer, the difference in K i corresponds to a difference in binding free energy of DG°= (1.7 ± 0.1) kcal/mol, which is typical for a hydrogen bond. These comparisons suggest that 4e and 4c likely bind to human CP4H1 in a manner similar to the corresponding pyridinedicarboxylates, except that their binding is stabilized further by additional enzymic interactions with the second carboxylate group.
Inhibition of PHD2
We reasoned that the second carboxyl group of 4e and 4c could allow for the selective inhibition of CP4Hs over other FAKGDs. This issue is, however, difficult to address in the absence of structural information about the catalytic domain of any human or mammalian CP4H. Although the structure of the N-terminal peptide binding domain of the a-subunit has been characterized with both X-ray crystallography 16, 17 and NMR spectroscopy, 15 the structure of the catalytic domain has remained elusive. Unlike with CP4H, there are numerous crystal structures available for PHD2, including some solved as a complex with AKG or AKG mimics. Moreover, preliminary SARs for PHD2 with respect to simple AKG mimics such as 3a, 3b, and 2 have already been established, facilitating a comparison between the SARs of CP4H1 and PHD2. 18 For example, 2 and 3a inhibit PHD2 at low micromolar concentrations, but 3b does not inhibit PHD2 even at high micromolar concentrations. These and other data suggest differences in the active sites of these essential FAKGDs that could be understood further using a combination of both chemical approaches and existing structural information.
Toward this end, we screened our library at 10 lM as inhibitors of PHD2. We found that, whereas 4c (and to a lesser extent 4b) inhibited PHD2, most other 2,2 0 -bipyridinedicarboxylates including 4e showed virtually no inhibition (Fig. 6) . Moreover, the inhibition observed for 4c was not greater than that observed for simple AKG mimics, such as 2 and 3a. These data are consistent with the hypothesis that 4c is accommodated in the PHD2 active site, but without the engagement of its 5 0 -carboxyl group in a favorable enzymic interaction. These data are also in agreement with examinations of available crystal structures of PHD2 (PDB entries 3ouj, 3ouh, 2hqu, and 2g1m), wherein the active site cleft opposite the AKG binding site is exposed to solvent. Using all extant data, we put forth schematic models of 2,2 0 -bipyridinedicarboxylates with CP4H1 and PHD2 (Fig. 7) .
Other isoforms of CP4H
We note that our investigations have focused on the CP4H1 holoenzyme rather than the CP4H2 and CP4H3 isoforms. This choice was largely due to the relative abundance of CP4H1 in most tissues compared to that of the other two isoforms. 11 Nonetheless,
BLAST experiments suggest high similarity between the three asubunits, with the a(I)-subunit 78 and 56% similar to the a(II)-and a(III)-subunits, respectively. Moreover, these similarities improve to >85 and >63% when considering only the catalytic domains. Given these high similarities, the SARs identified for CP4H1 (as well as the model put forth in Fig. 7A ) could also pertain to CP4H2 and CP4H3. 
Conclusion
The need for selective inhibitors of human CP4Hs with therapeutic potential is evident from the growing list of diseases associated with the overproduction of collagen. The lack of structural information available for mammalian CP4Hs has made the development of such inhibitors difficult, and the understanding of known inhibitors such as compounds 3b and 4e likewise evasive. Our investigations of the 2,2 0 -bipyridinedicarboxylate family reveal new information. For example, 3b was known to be a selective inhibitor of human CP4H compared to other FAKGDs, such as the PHDs, FIH, and JMJD2E. 18 These results, along with additional 0 -bipyridinedicarboxylate geometries in the conventional AKG binding mode, where the enhanced potency of these inhibitors stems from additional enzymic interactions in the distal active site, which has yet to be characterized. Fe(II) is likely chelated by Asp414, His412, and His483. 36 (B) Unlike CP4H, PHD2 accommodates only 4c in the AKG binding pocket. That finding and the similar potency of this compound compared to simple AKG mimics (e.g., 2 and 3a) are consistent with the formation of hydrogen bonds between the second carboxyl group and solvent. Fe(II) is chelated by Asp315, His313, and His374. 18 structure-activity relationships of 3b analogues, 23 led researchers to postulate that 3b could bind to CP4H in a manner that is distinct from the conventional AKG binding mode, possibly taking advantage of alternative coordination sites on the enzymic iron center. Our finding that 4c and 4e are competitive inhibitors of human CP4H1 with almost equal potency contrasts with the previous postulate and suggests that the AKG-binding pocket of this enzyme is likely able to accommodate two different inhibitor geometries (reminiscent of the geometries of either 3a or 3b) in the conventional AKG binding mode. Still, the exact structural and/or conformational features that allow for this accommodation are not yet understood.
Although achieving selectivity for CP4Hs over other FAKGDs is ideal, it is especially important to achieve selectivity over PHD2. For example, in hypoxic breast cancers, the expression of the CP4H a(I)-and a(II)-subunits is upregulated in a PHD2-dependent manner, which ultimately contributes to the metastatic potential of these tumors. 7 More specifically, the loss in PHD2 activity due to hypoxia allows the accumulation of the PHD2 substrate and transcription factor HIF-1a, which ultimately enhances the expression of these metastatically important CP4H a-subunits.
7 Although treatment with a CP4H inhibitor could be a viable strategy to disrupt breast cancer metastasis, that inhibitor must avoid inhibition of PHD2 so as to prevent a consequent increase in the target CP4Hs. Indeed, the poor performance of many previously characterized CP4H inhibitors in cells could be due, at least in part, to the off-target effects associated with inhibiting PHD2. Our finding that both 4c and 4e are substantially more potent towards human CP4H1 compared to simple AKG mimics, as well as the finding that this increased potency does not occur when inhibiting PHD2, suggests the existence of additional CP4H1 residues that can be used to achieve the desired selectivity. Although the identity of these residues is unclear, previous investigations of the 4e scaffold showed that additional functional groups such as anilides and sulfonamides are tolerated as replacements of the 5 0 -carboxylate, 23, 25 suggesting that the interaction(s) in this second site might not necessarily be Coulombic in nature. Lastly, we note that our data reveal that both compound 4c and compound 4e are potent inhibitors of CP4H1 and that inhibition arises largely through enzymic binding. Still, 4c and 4e do bind to free Fe(II), which could compromise therapeutic efficacy. Our future work will seek to modify these scaffolds to limit Fe(II) binding while maintaining selective affinity for CP4Hs.
Experimental section
General experimental procedures
Compounds 1, 3a, 3b, 4a, and 4e were from Sigma-Aldrich (St. Louis, MO). Compound 4b was from TCI America (Portland, OR). Compound 4g was from CMS Chemicals (Compton, UK). Biphenyl-4,4 0 -dicarboxylic acid was from Acros Organics (Geel, Belgium), and biphenyl-3,4 0 -dicarboxylic acid was from CombiBlocks (San Diego, CA). Phosphine ligands and phosphonium salts were from either Sigma-Aldrich or Strem (Newberryport, MA), stored in a desiccator, and used without further purification. Pd(OAc) 2 was from Sigma-Aldrich, stored in a desiccator, and used without further purification. HIF-1a peptide 556-574 was from AnaSpec (Fremont, CA) and used without further purification. All other reagent chemicals were from Sigma-Aldrich, Acros Organics, Combi-Blocks, Oakwood Products (West Columbia, SC), Enamine (Monmouth Junction, NJ), Bachem (Bubendorf, Switzerland), or Calbiochem-Novabiochem (San Diego, CA), and were used without further purification.
All glassware was flame-or oven-dried, and reactions were performed under N 2 (g) unless indicated otherwise. Dichloromethane and toluene were dried over a column of alumina. Dimethylformamide was dried over alumina and further purified through an isocyanate scrubbing column. Other anhydrous solvents were obtained in septum-sealed bottles. Flash chromatography was performed with columns of 40-63 Å silica gel, 230-400 mesh from Silicycle (Québec City, Canada). Thin-layer chromatography (TLC) was performed on plates 250-lm silica 60-F 254 from EMD Merck (Darmstadt, Germany) with visualization by UV light irradiation or staining with KMnO 4 . The phrase 'concentrated under reduced pressure' refers to the removal of solvents and other volatile materials using a rotary evaporator at water aspirator pressure (<20 torr) while maintaining water-bath temperature below 40°C. Residual solvent was removed from samples at high vacuum (<0.1 torr). The term 'high vacuum' refers to vacuum achieved by a mechanical belt-drive oil pump. All reported yields are unoptimized. The purity of all synthesized compounds was assessed by HPLC, and the purity of all final compounds was found to be greater than 95%.
Instrumentation
Melting points were determined with a PMA160 digital melting apparatus from Stanford Research Systems (Sunnyvale, CA). NMR spectra were acquired at ambient temperature with a DMX-400 Avance spectrometer or a Avance 500i spectrometer from Bruker (Billerica, MA) at the National Magnetic Resonance Facility at Madison (NMRFAM) and were referenced to TMS or a residual protic solvent. Some compounds exist as either mixtures of rotamers or tautomers that do not interconvert on the NMR timescale at ambient temperature and therefore exhibit multiple sets of NMR signals (as indicated). Electrospray ionization (ESI) and electron ionization (EI) mass spectrometry were performed with a Micromass LCT Ò and Micromass AutoSpec Ò instruments, respectively, from Waters (Milford, MA) at the Mass Spectrometry Facility in the Department of Chemistry at the University of Wisconsin-Madison. The progress of reactions catalyzed by prolyl 4-hydroxylases was determined by analytical HPLC using a system from Waters equipped with a 996 photodiode array detector and Empower 2 software. Compound purity was also determined using the Waters HPLC system above. Preparative HPLC was performed using a Prominence HPLC instrument from Shimadzu (Kyoto, Japan) equipped with two LC-20AP pumps, SPD-M20A photodiode array detector, and CTO-20A column oven. Iron complexes with bipyridine ligands were analyzed by spectrophotometry using a Cary 60 UV-vis spectrometer from Agilent Technologies (Santa Clara, CA). Protein concentrations were calculated from their absorbance at 280 nm as measured with a NanoVue Plus spectrophotometer from GE Healthcare using an extinction coefficient of 290,000 M À1 cm À1 for human CP4H 31 and 36,900 M À1 cm À1 for human PHD2. 32 IC 50 -and EC 50 -values were calculated from experimental data with Prism version 6.0 software from GraphPad Software (La Jolla, CA).
Production of recombinant human CP4H1
Human CP4H containing the a(I) isoform was produced heterologously in Origami B(DE3) Escherichia coli cells and purified as described previously. 31 
Assay of human CP4H1 activity in the presence of inhibitors
The catalytic activity of human CP4H1 was assayed as described previously. 31 Briefly, activity assays were carried out at 30°C in 100 lL of Tris-HCl buffer, pH 7.8, containing human CP4H1 (100 nM), inhibitor (0-500 lM), substrate (dansylGlyProProGlyOEt, 500 lM), FeSO 4 (50 lM), BSA (1 mg/mL), catalase (0.1 mg/mL), ascorbate (2 mM), DTT (100 lM), and a-ketoglutarate (100 lM).
Reaction mixtures were pre-incubated with or without inhibitor for 2 min at 30°C, after which the reaction was initiated by the addition of a-ketoglutarate. After 15 min, reactions were quenched by boiling for 45 s and centrifuged at 10,000g. The supernatant (20-50 lL) was injected into a Nucleodur Ò C18 Gravity reversedphase column (4.6 Â 250 mm, 5-lm particle size) from Macherey-Nagel (Bethlehem, PA). The column was eluted at 1 mL/min with a gradient of aqueous acetonitrile (20-45% over 20 min) containing 0.1% v/v TFA. The absorbance of the eluent was monitored at 289 nm. All assays were performed in triplicate. Data is reported as activity relative to control reactions lacking inhibitor, where activity is determined from the percent conversion of substrate to product. Dose-response curves were generated for each inhibitor by plotting the relative activity versus the log of the inhibitor concentration. IC 50 -values for each inhibitor were interpolated from the dose-response curves by non-linear regression using the sigmoidal dose-response function within the Prism software.
Production of human PHD2
A cDNA encoding human PHD2 181-426 possessing an N-terminal hexahistidine (His 6 ) tag (NHis 6 -PHD2 181-426 ) was cloned using the Gibson strategy, 33 and the encoded protein was produced and purified as described previously. 
Assay of human PHD2 activity in the presence of inhibitors
The catalytic activity of human PHD2 in the absence or presence of putative inhibitors was assayed as described previously. 32 Briefly, activity assays were carried out at 30°C in 100 lL of Tris-HCl buffer, pH 7.8, containing human NHis 6 -PHD2 181-426 (5 lM), inhibitor (0-10 lM), substrate (HIF-1a peptide 556-574 , 50 lM), FeSO 4 (50 lM), BSA (1 mg/mL), catalase (0.3 mg/mL), ascorbate (2 mM), DTT (1 mM), and a-ketoglutarate (35 
lM).
Reactions were pre-incubated with or without inhibitor for 2 min at 30°C, after which the reaction was initiated by the addition of a-ketoglutarate. After 10 min, reactions were quenched by boiling for 60 s and centrifugation at 10,000g. The supernatant (50 lL) was injected into a Nucleodur Ò C18 Gravity reversed-phase column (4.6 Â 250 mm, 5 lM particle size) from Macherey-Nagel. The column was eluted at 1 mL/min with a gradient of aqueous acetonitrile (5-56% over 34 min) containing 0.1% v/v TFA. The absorbance of the eluent was monitored at 218 nm. All assays were performed in triplicate. Data is reported as activity relative to control reactions lacking inhibitor, where activity is determined from the percent conversion of substrate to product.
Assay of Fe(II)-affinity of bipyridine compounds
The affinity of bipyridine compounds for Fe(II) was determined comparatively by measuring the half maximal concentration (EC 50 ) required for binding 20 lM Fe(II) (Fe 20 -EC 50 ) in sodium phosphate buffer, pH 7.0. Stock solutions of ligands were prepared in water. Stock solutions of FeSO 4 were prepared in H 2 O and used within 3 h of preparation. Ligand solutions (3-500 lM depending on affinity) were prepared in 10 mM sodium phosphate buffer, pH 7.0, after which Fe(II) stock solution was added to initiate complex formation. Solutions were allowed to equilibrate for 15 min, after which the absorbance was recorded at the k max for the complex under study. Absorbance values were corrected by subtracting the absorbance value in the absence of ligand. Dose-response curves were generated for each ligand by plotting the absorbance versus the log of the ligand concentration. Fe 20 -EC 50 values for each ligand were interpolated from the dose-response curves by non-linear regression using the sigmoidal dose-response function in Prism. All experiments were performed in triplicate.
Determination of Fe(II) complex stoichiometry
The stoichiometry of complexes formed by bipyridine ligands and Fe(II) was estimated with Job's method. 34, 35 Briefly, solutions were prepared such that the concentration of ligand and Fe(II) were kept at 0.4 mM, but the mole fraction of the ligand was varied from 0 to 1. Stock solutions of ligands were prepared in water. Stock solutions of FeSO 4 were prepared in water and used within 3 h of preparation. Mixtures were prepared in 10 mM sodium phosphate buffer, pH 7.0, and complex formation was initiated by the addition of the Fe(II) solution. Solutions were allowed to equilibrate for 15 min, after which the absorbance was recorded at the appropriate k max for the complex under study. Absorbance values were corrected by subtracting the absorbance value of a blank solution in the absence of FeSO 4 , after which the values were normalized relative to the mixture with the highest absorbance value. All experiments were performed at least in duplicate. Job plots were constructed by plotting the normalized absorbance versus the mole fraction of bipyridine ligand, after which the stoichiometry of the complex was estimated from the value on the abscissa of the point of intersection for the two best-fit lines approaching the point of maximum absorbance.
Determination of compound purity
All synthesized compounds were analyzed by HPLC to determine their purity. The analyses were performed on the Waters HPLC system using a Nucleodur Ò C18 Gravity reversed-phase column (4.6 Â 250 mm, 5-lm particle size) from Macherey-Nagel. , 3.3 mmoles) , and 3-methoxycarbonylpyridine Noxide (2000 mg, 13 mmoles) were added to a dried flask. The flask was fitted with a reflux condenser capped with a septum, evacuated, and purged with N 2 (g) ($5 times). Dry toluene (22 mL) was added via syringe, and the reaction mixture was stirred at 110°C for 18 h. The reaction mixture was cooled to room temperature and filtered through Celite Ò , and the filtrate was concentrated under reduced pressure. The crude product was then purified by chromatography on silica (15% acetone in 1:1 DCM/hexanes) to afford the title compound (537 mg, 57%) as a pale orange solid with mp 170.6-174.1°C. 4.10.5. 5-Methoxycarbonyl-2-(6-methoxycarbonylpyridin-2-yl)pyridine N-oxide Pd(OAc) 2 (10.1 mg, 0.045 mmoles), [P(t-Bu) 3 H]BF 4 (39.2 mg, 0.14 mmoles), K 2 CO 3 (248 mg, 1.8 mmoles), methyl 2-bromopicolinate (195 mg, 0.9 mmoles), and 3-methoxycarbonylpyridine Noxide (553 mg, 3.6 mmoles) were added to a dried flask. The flask was fitted with a reflux condenser capped with a septum, evacuated, and purged with N 2 (g) ($5 times). Dry toluene (6.0 mL) was added via syringe, and the reaction mixture was stirred at 110°C for 24 h. The reaction mixture was cooled to room temperature and filtered through Celite Ò , and the filtrate was concentrated under reduced pressure. The crude product was then purified by chromatography on silica (EtOAc) to afford the title compound (135 mg, 52%) as a pale orange solid with mp 159.7-162.0°C. The ensuing reaction mixture was stirred at 60°C until the starting material was consumed completely, as judged by TLC (6 h). The reaction mixture was quenched by the dropwise addition of saturated aqueous Na 2 CO 3 (10 mL) while stirring on ice. The product was extracted with CHCl 3 (4 Â 10 mL), and the combined organics were dried over Na 2 SO 4 (s) and concentrated under reduced pressure to afford the title compound (69 mg, 98%) as a pale yellow solid with mp 163.1-165.2°C. 4.10.8. Dimethyl 2,2 0 -bipyridine-5,6 0 -dicarboxylate 5-Methoxycarbonyl-2-(6-methoxycarbonylpyridin-2-yl)pyridine N-oxide (127 mg, 0.44 mmoles) was dissolved in dry CHCl 3 (14.7 mL), after which PCl 3 (50 lL, 0.53 mmoles) was added. The reaction mixture was stirred at 60°C until the starting material was consumed completely, as judged by TLC. The reaction was quenched by the dropwise addition of saturated aqueous Na 2 CO 3 (15 mL) while stirring on ice. The product was extracted with CHCl 3 (5 Â 15 mL), and the combined organics were dried over Na 2 SO 4 (s) and concentrated under reduced pressure to afford the title compound (61 mg, 53%) as a pale yellow solid with mp 170.9-172.3°C. 1 0 -bipyridine-4,5 0 -dicarboxylate (482 mg, 1.8 mmoles) and KOH (460 mg, 7.1 mmoles) were added to a vial. MeOH (9.0 mL) was added to the vial, and the resulting reaction mixture was heated to 60°C until the starting material was consumed completely, as judged by TLC. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was dissolved in water (20 mL). The aqueous layer was washed with EtOAc (1 Â 20 mL), after which the product was precipitated from the aqueous layer by adjusting to pH 3-4 with 1 M HCl. After cooling to 4°C, the product was filtered, washed with water (3 Â 5 mL), and dried in vacuo to afford 4c (412 mg, 95%) as an off-white solid with mp >260°C. 0 -bipyridine-4,6 0 -dicarboxylate (75 mg, 0.28 mmoles) and KOH (80 mg, 1.12 mmoles) were added to a vial. MeOH (8.0 mL) was added to the vial, and the resulting reaction mixture was heated to 60°C until the starting material was consumed completely, as judged by TLC. The reaction mixture was cooled and concentrated under reduced pressure, after which the crude product was dissolved in water (2 mL). The aqueous layer was washed with EtOAc (1 Â 2 mL), after which the product was precipitated from the aqueous layer by adjusting to pH 3-4 with 1 M HCl. After cooling to 4°C, the product was filtered, washed with water (3 Â 1 mL), and dried in vacuo to afford 4d (49 mg, 73%) as an offwhite solid with mp >260°C. 0 -bipyridine-5,6 0 -dicarboxylate (39 mg, 0.14 mmoles) and KOH (40 mg, 0.57 mmoles) were added to a vial. MeOH (4.0 mL) was added to the vial, and the resulting reaction mixture was heated to 60°C until the starting material was consumed completely, as judged by TLC. The reaction mixture was cooled and concentrated under reduced pressure, after which the crude product was dissolved in water (2 mL). The aqueous layer was washed with EtOAc (1 Â 2 mL), after which the product was precipitated from the aqueous layer by adjusting to pH 3-4 with 1 M HCl. After cooling to 4°C, the product was filtered, washed with water (3 Â 1 mL), and dried in vacuo to afford 4f (20 mg, 57%) as an offwhite solid with mp >260°C. 4.10.12. N-(Methoxyoxalyl)glycine ethyl ester HGlyOEtÁHCl (333 mg, 2.4 mmoles) and DMAP (29.1 mg, 0.24 mmoles) were added to a round-bottom flask. The flask was capped with a septum and purged with N 2 (g) ($5 times). DCM (6 mL) was added, and the reaction mixture was cooled in an ice bath. DIEA (750 lL, 4.3 mmoles) and monomethyl oxalyl chloride (200 lL, 2.2 mmoles) were added via syringe, and the reaction was stirred and allowed to come to room temperature. After 6 h, the reaction mixture was quenched on ice by the dropwise addition of a saturated aqueous solution of ammonium chloride (10 mL). The organic layer was collected, and the aqueous layer was extracted with EtOAc (3 Â 10 mL). The combined organic extracts were dried over Na 2 SO 4 (s), and concentrated under reduced pressure to afford a crude yellow oil. The crude product was then purified by chromatography on silica (70% v/v EtOAc in hexanes) to afford the title compound (416 mg, 92%) as a white solid with mp 58. 4.10.13. N-Oxalylglycine (2) N-(Methoxyoxalyl)glycine ethyl ester (100 mg, 0.53 mmoles) and KOH (88 mg, 1.6 mmoles) were added to a vial. MeOH (5.0 mL) was added to the vial, and the resulting reaction mixture was heated to 60°C until the starting material was consumed completely, as judged by TLC. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The crude product was dissolved in water (2 mL), and the pH of the resulting solution was adjusted to 3-4 with 1 M HCl. The aqueous solution was concentrated under reduced pressure, and the residue was dissolved in boiling EtOAc. The solution was cooled, filtered, and concentrated under reduced pressure to a viscous oil. The oil was dissolved in a minimal amount of DCM, diluted with hexanes, and concentrated under reduced pressure. This procedure was repeated 3 times, after which the product was dried under high vacuum to afford 2 (77 mg, 99%) as a white solid with mp 104. were added to a round-bottom flask. The flask was capped with a septum and purged with N 2 (g) ($5 times). DMF (28 mL) and DIEA (1.9 mL, 11.2 mmoles) were added via syringe, and the reaction mixture was stirred at room temperature until the reaction was judged to be complete by TLC (approximately 48 h). The reaction mixture was concentrated under reduced pressure, and the resulting residue dissolved in EtOAc (50 mL). The organic layer was washed with 5% w/v KHCO 3 (2 Â 25 mL), 5% w/v KHSO 4 (2 Â 25 mL), and brine (1 Â 25 mL). The combined organics were dried over Na 2 SO 4 (s) and concentrated under reduced pressure to a crude yellow oil. The crude product was then purified by chromatography on silica (0-2% v/v MeOH in EtOAc) to yield the title compound (755 mg, 63%) as a pale yellow oil.
1 H NMR (400 MHz, 
N-Dansylglycyl-(2S)-prolyl-(2S)-prolylglycine ethyl ester (dansylGlyProProGlyOEt)
A suspension of CbzProProGlyOEt (755 mg, 1.8 mmoles) and Pd/C (76 mg) in MeOH (18 mL) was stirred under an atmosphere of H 2 (g) for 3 h. The reaction mixture was filtered through a pad of Celite Ò and then concentrated under reduced pressure to a pale yellow viscous oil (553 mg). The oil was dissolved in DCM (5.9 mL) and cooled to 0°C, after which dansylGlyOH (586 mg, 2.0 mmoles) and PyBroP Ò (973 mg, 2.3 mmoles) were added. The flask was capped with a septum and purged with N 2 (g). DIEA (0.63 mL) was added via syringe, and the reaction mixture was stirred at 0°C for 5 min. The reaction mixture was allowed to come to room temperature and stirred for an additional 6 h. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by chromatography on silica (2% v/v MeOH in 
